Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors

Summary

HWK-007-101 is a multicenter, open-label, first-in-human (FIH) Phase 1 study evaluating HWK-007, a protein tyrosine kinase 7 (PTK7)-targeted antibody drug conjugate (ADC), in adult participants with advanced or metastatic solid tumors known to be expressing PTK7. The study employs a sequential dose escalation and dose expansion design without a control group.

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

• Endometrial Cancer
• Ovarian Cancer
• Ovarian Cancer Metastatic
• Ovarian Cancer Metastatic Recurrent
• Non-squamous EGFR Wt NSCLC
• Platinum Resistant Ovarian Cancer
• PROC

Eligibility basics and study details

Study type

Interventional

Phase

Phase 1

Ages

18 years and older

Sex

All

Healthy volunteers

Not accepted

Sponsor

Whitehawk Therapeutics, Inc.

Last updated on ClinicalTrials.gov

August 5, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites